title: Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
abstract: The best treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) is still debated. To guide clinical management of these patients and suggest the priorities for clinical research in this field, an International Expert Panel met in Naples, Italy, on April 19 to 20, 2004. Results and conclusions based on a review of evidence available in the literature to date are presented in this article. A comprehensive geriatric assessment is recommended to better define prognosis and to predict tolerance to treatment. In the first randomized study dedicated to elderly NSCLC patients, single-agent vinorelbine showed superiority over supportive care alone, both in terms of survival and quality of life. In a large randomized trial, gemcitabine plus vinorelbine failed to show any advantage over either agent alone. Subset analyses suggest that the efficacy of platinum-based combination chemotherapy is similar in fit older and younger patients, with an acceptable increase in toxicity for elderly patients. These data should be interpreted cautiously because retrospective subgroup analyses are encumbered by selection bias; hence, randomized trials dedicated to platinum-based chemotherapy for nonselected elderly patients are warranted. Several promising biologic therapies are under investigation; however, with present data, target-based agents as first-line treatment for elderly NSCLC patients are not yet recommended. Clinical research, with trials specifically designed for elderly patients, is mandatory. With the current evidence, single-agent chemotherapy with a third-generation drug (vinorelbine, gemcitabine, a taxane) should be the recommended option for nonselected elderly patients with advanced NSCLC. Platinum-based chemotherapy is a viable option for fit patients with adequate organ function. Best supportive care remains important, in addition to chemotherapy or as the exclusive option for patients who are unsuitable for more aggressive treatment.
authors.affiliation: Division of Medical Oncology, "S.G. Moscati" Hospital, Via Circumvallazione 68, 83100 Avellino, Italy. cgridelli@libero.it
authors.forename: Cesare
authors.initials: C
authors.lastname: Gridelli
authors.forename: Matti
authors.initials: M
authors.lastname: Aapro
authors.forename: Andrea
authors.initials: A
authors.lastname: Ardizzoni
authors.forename: Lodovico
authors.initials: L
authors.lastname: Balducci
authors.forename: Filippo
authors.initials: F
authors.lastname: De Marinis
authors.forename: Karen
authors.initials: K
authors.lastname: Kelly
authors.forename: Thierry
authors.initials: T
authors.lastname: Le Chevalier
authors.forename: Christian
authors.initials: C
authors.lastname: Manegold
authors.forename: Francesco
authors.initials: F
authors.lastname: Perrone
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
authors.forename: Frances
authors.initials: F
authors.lastname: Shepherd
authors.forename: Luigi
authors.initials: L
authors.lastname: De Petris
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Maio
authors.forename: Corey
authors.initials: C
authors.lastname: Langer
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018579:Patient Selection; D011379:Prognosis; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents